Epoetin-Β treatment in patients with cancer chemotherapy-induced anaemia: The impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events

British Journal of Cancer

Volumn 101, Issue 12, 2009, Pages 1961-1971

  Aapro, M ^a   Osterwalder, B ^b   Scherhag, A ^b,c   Burger, H U ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anaemia; Epoetin ; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TUMOR GROWTH; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THROMBOEMBOLISM;

EID: 71649091673     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605255     Document Type: Article

References (51)

1. Aapro M, Scherhag A, Burger HU (2008a) Effect of treatment with epoetin beta on survival, tumour progression and thromboembolic events in patients with metastatic cancer: an updated meta-analysis of 12 randomized controlled studies including 2301 patients. Br J Cancer 99(1): 14-22
2. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger H-U (2008b) Effect of once weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy-results of the BRAVE study. J Clin Oncol 26: 592-598
3. Aapro M, Barnadas A, Leonard RC, Marangolo M, Untch M, Ukarma L, Burger H-U, Scherhag A, Osterwalder B (2009) What is the impact of anti-thrombotic therapy and risk factors on the frequency of thrombo-vascu-lar events in patients with metastatic breast cancer receiving epoetin beta? Eur J Cancer, epub ahead of print, 29 July 2009, doi:10.1016/j.ejca.2009.06.31
4. Aapro M, Link H (2008) September 2007 Update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. The Oncologist 13(suppl 3): 33-36
5. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A (2001) Erythropoietin and erythropietin receptor expression in human cancer. Cancer Res 61: 3561-3565
6. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohistochem-ical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95(5): 969-981
7. Anderson FA, Spencer FA (2003) Risk factors for venous thromboembo-lism. Circulation 107: I-9-I-16
8. Antonadou D, Cardamakis E, Puglisi M (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur J Cancer 37(Suppl 6): A530
9. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82(7): 911-918
10. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low haematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590
11. Bokemeyer C, Oechsle K, Hartmann J-T (2005) Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest 35(Suppl 3): 26-31
12. ̈ Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P, European Organization for research and Treatment of Cancer (EORTC) Taskforce for the Elderly (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43: 258-270
13. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489-498
14. Bohlius J, Wilson J, Seidenfeld S, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennet CL, Langensiepen S, Hyde C, Engert A (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews Article no.: CD003407. DOI: 10.1002/14651858.CD003407.pub4
15. Bohlius J, Brillant C, Clarke M, Kluge S, Napoli M, Piper M, Rades D, Schumacher M, Schmidlin K, Schwarzer G, Seidenfeld J, Steensma DP, Trelle S, Weingart O, Zwahlen M, Egger M, Engert A (2008) Recombinant human erythropoiesis stimulating agents in cancer patients: individual patient data meta-analysis on behalf of the EPO IPD Meta-analysis Collaborative Group. Blood 112: 4675
16. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532-1542
17. Boogaerts M, Coiffier B, Kainz C, Epoetin Beta QOL Working Group (2003) Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88: 988-995
18. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91: 2214-2221
19. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegier L, Essers U, Greil R, Grossi A, Jager G, Le Mevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453
20. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95: 888-895
21. Glaser CM, Millesi W, Kornek GV, Long S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705-715 (Pubitemid 32519598)
22. Henke M, Laszig R, Rube C, Schafer U, Hasse KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled, trial. Lancet 362: 1255-1260
23. Janecka IP (2004) Letter. Lancet 363: 992
24. Kelleher DK, Thews O, Vaupel P (1998) Can Erythropoietin Improve Tumor Oxygenation? Strahlentherapie und Onkologie 174(Suppl IV): 20-23
25. Kettelhack C, Hones C, Messinger D, Schlag PM (1998) Randomized multicenter trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 85: 63-67
26. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH (2008) Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168(21): 2377-2381
27. Leyland-Jones B, Mahmud S (2004) Erythropoietin to treat anaemia in patients with head and neck cancer [letter]. Lancet 363: 80
28. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandi S, Makhson A, Roth A, Dodwell D, Basalga J, Biakhov M, Valuckas K, Voznui E, Lui X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anaemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972
29. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapaport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 19: 2865-2874
30. Ludwig H, van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer 40: 2293-2306
31. Luksenburg H, Weir A, Wager R (2004) FDA Briefing Document: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy, http://www.fda.gov/ohrms/ dockets/ac/cder04.html#oncologic, accessed 15 September 2009
32. Mittelman M, Neumann D, Peled A, Kanter P, Haren-Ghera N (2001) Erythropoietin induces tumour progression and antitumour immune responses in murine myeloma models. Proc Natl Acad Sci USA 98: 5181-5186
33. Nicolaides AN, Irving D (1975) Clinical factors and the risk of deep venous thrombosis. In Thromboembolism Etiology Advances in Prevention and Management Nicolaides A (ed) 193-204. University Park Press: Baltimore, MD
34. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrman R, Netter-Pinon J, Tubiana-Mathiew N, Zwierzina H (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255-260
35. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkdyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494
36. Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najmen A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. Blood 87:2675-2682
37. Österborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: a long-term follow up of a large randomized study. Br J Haematol 129: 206-209
38. Overgaard J, Hoff C, Sand Hansen H, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen L, Evensen J (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer Group DAHANCA 10. Eur J Cancer Supplements 5(6): 7
39. Rau B, Schlag PM, Willeke F, Herforth C, Stephen P, Frake W (1998) Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Eur J Cancer 34: 992-998
40. Smith Jr RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26(7): 1040-1050
41. Strauss HG, Haensgen G, Dunst J, Hayward CR, Burger HU, Scherhag A, Koelbl H (2008) Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer 18(3): 515-524
42. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stusche M, Thews O, Vaupel P (2003) Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J radiat Oncol Biol Phy 55: 1358-1362
43. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Haeven JJ, Reeds NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristenson GB, van Tinteren H, Ehmer B (1998) Controlled, multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174-182
44. Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61: 1358-1361
45. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S (2009) Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180(11): E62-E71. DOI:10.1503/cmaj.090470
46. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gatkey J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220
47. Vaupel P, Mayer A (2004) Erythropoietin to treat anaemia in patients with head and neck cancer [letter]. Lancet 363: 992
48. Wheeler HB, Anderson FA, Cardullo PA, Patwardhan NA, Jian-Ming L, Cutler BS (1982) Suspected deep vein thrombosis. Management by impedance plethysmography. Arch Surg 117(9): 1206-1209
49. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C (2007) A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11: 1-202
50. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25(9): 1021-1023
51. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029